Javad Shahidi
- Oncology top 2%
- Radiology, Nuclear Medicine and Imaging top 2%
- Pulmonary and Respiratory Medicine top 5%
- Cancer Research top 10%
- Molecular Biology
- Co-authors
- Hiroji IwataKenji TamuraShanu ModiToshihiko DoiShunji TakahashiJunji TsurutaniMasahiro SugiharaHaeseong Park
- Topics
- HER2/EGFR in Cancer Research (19 papers)Lung Cancer Treatments and Mutations (14 papers)Advanced Breast Cancer Therapies (8 papers)
- Partner nations
- United StatesSpainCanada
In The Last Decade
Javad Shahidi
42 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Oncology 1.3k
- Radiology, Nuclear Medicine and Imaging 595
- Pulmonary and Respiratory Medicine 594
- Cancer Research 269
- Molecular Biology 159
Countries citing papers authored by Javad Shahidi
This map shows the geographic impact of Javad Shahidi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javad Shahidi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javad Shahidi more than expected).
Fields of papers citing papers by Javad Shahidi
This network shows the impact of papers produced by Javad Shahidi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javad Shahidi. The network helps show where Javad Shahidi may publish in the future.
Co-authorship network of co-authors of Javad Shahidi
This figure shows the co-authorship network connecting the top 25 collaborators of Javad Shahidi. A scholar is included among the top collaborators of Javad Shahidi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javad Shahidi. Javad Shahidi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 1 | |
| 3 | 94 | |
| 4 | Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Studybreakdown → | 551 |
| 5 | 3 | |
| 6 | Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 studybreakdown → | 258 |
| 7 | 162 | |
| 8 | 2 | |
| 9 | 22 | |
| 10 | 2 | |
| 11 | 6 | |
| 12 | 10 | |
| 13 | 5 | |
| 14 | 2 | |
| 15 | 2 | |
| 16 | 54 | |
| 17 | 2 | |
| 18 | 7 | |
| 19 | 66 | |
| 20 | Treatment and prognosis of epithelial ovarian cancer: five year multi-center study. | 2 |
About Javad Shahidi
Javad Shahidi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 42 papers that have together received 1.6k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (19 papers), Lung Cancer Treatments and Mutations (14 papers) and Advanced Breast Cancer Therapies (8 papers). The work is most often cited by research in Oncology (1.3k citations), Radiology, Nuclear Medicine and Imaging (595 citations) and Pulmonary and Respiratory Medicine (594 citations). Javad Shahidi has collaborated with scholars based in United States, Spain and Canada. Frequent co-authors include Hiroji Iwata, Kenji Tamura, Shanu Modi, Toshihiko Doi, Shunji Takahashi, Junji Tsurutani, Masahiro Sugihara, Haeseong Park, Ian E. Krop and Caleb Lee. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.